Edit
Sperogenix Therapeutics Limited Homepage
http://en.sperogenix.com/Last activity: 05.07.2021
Probably Closed
Sperogenix Therapeutics is a platform focusing on development and commercialization of Rare Diseases Medications in China , provide clinically accessible products for rare disease patients and successful commercial solutions for rare disease therapeutics in China.
Employees: 51-200
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | LAV | lavfund.co... |
Mentions in press and media 4
| Date | Title | Description |
| 05.07.2021 | Abbisko and Sperogenix Announce An Exclusive Agreement to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China | SHANGHAI, BEIJING, HONG KONG, July 5, 2021 /PRNewswire/ -- Sperogenix (Shanghai) MedTech Co., Ltd. ("Sperogenix"), a subsidiary of Sperogenix Therapeutics (platform company for development and commercialization of rare diseases me... |
| 08.10.2020 | Minoryx Therapeutics y Sperogenix Therapeutics firman un acuerdo de licencia exclusivo para desarrollar y comercializar leriglitazona en China continental, Hong Kong y Macao | Sperogenix Therapeutics, una plataforma dedicada al desarrollo y comercialización de terapias para enfermedades raras en China, y Minoryx Therapeutics, una empresa especializada en el desarrollo de tratamientos innovadores para enfermedades... |
| 08.10.2020 | Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau | Sperogenix Therapeutics, a platform company dedicated to developing and commercializing rare disease therapeutics in China, and Minoryx Therapeutics, a company that specializes in the development of innovative treatments for orphan Central ... |
| 24.09.2020 | Minoryx, participada por firmas de VC, cierra un acuerdo de licencia con la farmacéutica china Sperogenix para el fármaco leriglitazona | 24/09/2020 Nota de prensa MINORYX, PARTICIPADA POR FIRMAS DE VENTURE CAPITAL, CIERRA UN ACUERDO DE LICENCIA CON LA FARMACÉUTICA CHINA SPEROGENIX PARA EL FÁRMACO LERIGLITAZONA. Minoryx, participada por firmas de venture capital, recibirá ... |